Breathe Easy Therapeutics is developing a range of cystic fibrosis (CF) specific formulations and medical devices to provide better tools for clinicians and patients dealing with this life shortening illness.
Cystic Fibrosis is a genetic illness affecting the lungs and digestive systems of approximately 75,000 people worldwide. In the US, the life expectancy of a person with CF is around 37 years. CF qualifies as an orphan illness under the FDA drug development framework which means that there is a faster clinical trial format avaliable.
Breathe Easy is developing a nebulised drug, Citramel, which can be used on its own or to complement existing CF treatments. Citramel, is currently in Phase I/IIa trials.